

EBV gene expression in laser-cut immune infiltrates from the MS brain

MS case	nº laser-cut immune infiltrates EBV positive/analysed (% positive)	Localization of EBV positive samples	EBV latent transcripts	EBV lytic transcripts
MS79	2/6 (33%)	Meninges #1	EBNA3A	
		Meninges #2	EBNA3A LMP1	gp350/220
MS92	7/13 (54%)	Meninges #1	LMP1	
		Meninges #2	LMP1	
		Meninges #3	EBER1 EBNA3A	gp350/220
		WM #4	EBER1 EBNA3A LMP1	
		WM #5	LMP1	
		WM #6	EBNA3A	BZLF1
		WM #7	EBER1	
MS121	2/7 (29%)	WM #1	EBER1	
		WM #2	EBER1 EBNA3A	
MS160	1/2 (50%)	Meninges #1	EBER1 EBNA3A	
MS176	2/5 (40%)	Meninges #1	LMP1	
		WM #2	EBNA3A LMP1	
MS180	9/16 (56%)	Meninges #1	LMP1	
		Meninges #2	EBER1 LMP1	
		Meninges #3		BZLF1
		Meninges #4		BZLF1
		Meninges #5	EBER1	
		WM #6	EBER1	
		WM #7	EBER1	
		WM #8	EBER1	
		WM #9	LMP1	
MS234	4/6 (67%)	Meninges #1	EBER1	
		Meninges #2	EBER1	
		Meninges #3	EBER1 LMP2A	
		Meninges #4	EBER1 LMP1	
MS330	2/2 (100%)	Meninges #1	EBER1 LMP1 LMP2A	
		Meninges #2	LMP1	
MS407	2/11 (18%)	Meninges #1	EBER1	
		Meninges #2	LMP2A	

The fraction of microdissected samples with detectable EBV gene expression from 9 of 11 MS cases analyzed and the localization of the EBV+ immune infiltrates for each MS case are shown in the 2nd and 3rd column, respectively. The EBV latent and lytic transcripts detected in the individual immune infiltrates are shown in the 4th and 5th column, respectively.